![](https://investorshub.advfn.com/uicon/8777.png?cb=1703671008)
Sunday, December 23, 2018 12:48:37 PM
More on the Japanese accelerated approval program:
Criteria for designation
Regenerative medical products for diseases in urgent need of innovative therapy that may satisfy the following four conditions:
1. Innovativeness of the products,with novel mechanism of action;
2. The target medical condition should be one of the following:
a. serious or life threatening medical condition; or
b. medical condition with persistent symptoms (conditions
interfering with normal activities of daily living)
for which there is no other curative treatment
3. Highly effective treatment against the target medical condition. There is no other therapy for the target medical condition, or the symptoms of patients
are expected to be significantly improved through use of the product as compared to the efficacy of existing therapies (including the case where
safety is expected to be improved significantly);
4. Develop the product rapidly and file an application for approval in Japan, ahead of other countries. The sponsor of the product intend to file an initial
application for approval in Japan, including the case where simultaneous applications are planned to be made in both Japan and other countries.
Advantage of designation
The SAKIGAKE designation system should allow the production of innovative medical products ahead of other countries with the shortest possible development and
review process. The following measures shall be used:
1. Consistent prioritized consultation by the Pharmaceutical Medical Devices Agency (PMDA);
2. Preapplication consultation in which de facto review is started with data that can be submitted before the application for approval;
3. Prioritized review aiming for a further reduction in the total review period (target total review time is 6 months);
4. Assigning a manager as a concierge. Concierge coordinates sponsor and MHLW/PMDA to toward approval including conformity assurance,
quality management, safety measures and review;
5. Strengthening postmarketing safety measures including the extension of the reexamination period.
Preapplication consultation includes the following five menus:
1. Quality;
2. Nonclinical;
3. Clinical including plan for postmarketing data collection;
4. Good Clinical Practice (GCP)/ Good Laboratory Practice (GLP) compliance; and
5. Good Gene, Cellular and Tissuebased Products Manufacturing Practice (GCTP) compliance. After the PMDA’s de facto review and onsite inspection,
the sponsor of the product files the application for approval in Japan (Table 1).
Steps for the SAKIGAKE designation Under the current framework, MHLW solicits candidate products
that satisfy the above criteria, and conducts a hearing on the candidate products in preparatory evaluation. The potential candidates meeting these specified criteria are invited to apply as candidates
for SAKIGAKE designation. MHLW evaluates the applied products based on priorities set through review of the applications by PMDA and the products judged to be excellent are selected or SAKIGAKE designation. MHLW reports to the Pharmaceutical Affairs and Food Sanitation Council and then designation results are made public. After the three rounds of applications, nine regenerative medical products (Table 2), 16 pharmaceuticals, six medical devices and one in vitro diagnostic have been assigned for SAKIGAKE designation [10].
ACCELERATED DEVELOPMENT OF INNOVATIVE REGENERATIVE MEDICAL PRODUCTS
Early approval system for regenerative medical products On November 2014, the Pharmaceutical Affairs Law was revised and renamed the Pharmaceuticals, Medical Devices and Other Therapeutic Products Act (PMD Act) [11]. Regenerative medical products are defined as:
1. Processed (more than minimal manipulation) live human/animal cells that are intended to be used for either:
a. The reconstruction, repair or formation of structures or functions of the human body; or
b. The treatment or prevention of human diseases
2. Gene therapy The regenerative medical prod ucts considered are mainly those satisfying unmet medical needs (serious or life threatening illnesses). Given that, in regenerative medicine products, there is a high vari ability in the quality of cells, manufacturing capacity, mechanism of action, number of patients with the target medical condition, clinical positioning of products etc., it would require longterm collection of clinical data for confirmation of effectiveness and safety. The PMD Act provides the option of a new pathway to obtain conditional and time-limited approval for regenerative medical products to achieve the early practical application. To obtain conditional and time limited approval, exploratory clinical trials are required that predict a reasonable likelihood of clinical benefit (for example, by using a surrogate endpoint). Following the conditional and time-limited approval, a confirmatory clinical study and followup patient safety measures are required to prepare for a further approval process within a maximum period of 7 years. Toward the full approval (second approval) review after the conditional and time-limited approval (first approval), it is necessary to construct a feasible plan to confirm effectiveness and safety before the expiration of conditional and time-limited approval. In order to ensure that products with uncon firmed effectiveness do not remain on the market, the new regulation gives MHLW a clear legal author ity to withdraw approval during the second approval process. In September 2015, HeartSheet, a skeletal myoblast sheet product for the treatment of severe heart failure, was the first product granted conditional and time-limited approval [12] (available online; for assessment report see [13]). The regenerative medical products that received SAKIGAKE designation as regenerative medical product targets for a serious or life threatening medical condition are good candidates to obtain conditional and time-limited approval.
insights.bio/cell-and-gene-therapy-insights/wp-content/uploads/sites/2/2018/07/Maruyama-Expert-Insight.pdf
Recent AVXL News
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/06/2024 09:21:05 PM
- Anavex Life Sciences Reports Fiscal 2024 Third Quarter Financial Results and Provides Business Update • GlobeNewswire Inc. • 08/06/2024 11:30:00 AM
- Anavex Life Sciences to Announce Fiscal 2024 Third Quarter Financial Results on Tuesday, August 6, 2024 • GlobeNewswire Inc. • 08/01/2024 11:30:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/30/2024 09:20:53 PM
- Anavex Life Sciences Announces Translational Biomarker Data for ANAVEX®2-73 (blarcamesine) in Fragile X Syndrome (Major Cause of Autism) at the 19th NFXF International Fragile X Conference • GlobeNewswire Inc. • 07/30/2024 11:30:00 AM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 07/29/2024 09:21:49 PM
- Results from Anavex Life Sciences Landmark Phase IIb/III Trial of Blarcamesine Presented at Alzheimer's Association Conference • GlobeNewswire Inc. • 07/28/2024 09:00:00 PM
- Anavex Life Sciences to Present at the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference • GlobeNewswire Inc. • 06/20/2024 11:30:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/17/2024 11:30:10 AM
- Anavex Life Sciences Announces Expansion of Leadership Team • GlobeNewswire Inc. • 05/22/2024 11:30:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/17/2024 10:01:00 AM
- Anavex Life Sciences to Present at the H.C. Wainwright 2nd BioConnect Investor Conference at NASDAQ • GlobeNewswire Inc. • 05/14/2024 11:30:00 AM
- Shareholders that lost money on Anavex Life Sciences Corporation(AVXL) Urged to Join Class Action - Contact The Gross Law Firm to Learn More • PR Newswire (US) • 05/10/2024 09:45:00 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/09/2024 08:35:55 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/09/2024 12:00:30 PM
- Anavex Life Sciences Reports Fiscal 2024 Second Quarter Financial Results and Provides Business Update • GlobeNewswire Inc. • 05/09/2024 11:30:00 AM
- The Gross Law Firm Announces the Filing of a Securities Class Action on Behalf of Anavex Life Sciences Corporation(AVXL) Shareholders • PR Newswire (US) • 05/07/2024 09:45:00 AM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 05/06/2024 10:03:33 AM
- Anavex Life Sciences Corporation Sued for Securities Law Violations - Contact The Gross Law Firm Before May 13, 2024 to Discuss Your Rights - AVXL • PR Newswire (US) • 05/03/2024 09:45:00 AM
- Anavex Life Sciences to Announce Fiscal 2024 Second Quarter Financial Results on Thursday, May 9th, 2024 • GlobeNewswire Inc. • 05/02/2024 11:30:00 AM
- May 13, 2024 Deadline: Contact The Gross Law Firm to Join Class Action Suit Against AVXL • PR Newswire (US) • 04/26/2024 09:45:00 AM
- Contact The Gross Law Firm by May 13, 2024 Deadline to Join Class Action Against Anavex Life Sciences Corporation(AVXL) • PR Newswire (US) • 04/19/2024 09:45:00 AM
- The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of May 13, 2024 in Anavex Life Sciences Lawsuit - AVXL • PR Newswire (US) • 04/16/2024 09:45:00 AM
- Class Action Filed Against Anavex Life Sciences Corporation (AVXL) - May 13, 2024 Deadline to Join - Contact The Gross Law Firm • PR Newswire (US) • 04/12/2024 09:45:00 AM
HealthLynked Corp. Announces Second Quarter and First Half 2024 Results: Continued Cost Reductions Set the Stage for Strategic Shift to App-Based Technology Services • HLYK • Aug 16, 2024 8:00 AM
PickleJar Announces Official Name Change and New Ticker Symbol • NREG • Aug 15, 2024 2:23 PM
VAYK's Q2 Profit Added to Accumulated Net Profit of Over $2.2 Million In 18 Months • VAYK • Aug 15, 2024 9:07 AM
Swifty Global Reports Strong Q2 Performance and Prepares for Major Exchange Uplisting • DRCR • Aug 15, 2024 9:04 AM
Mayback's Global Entertainment Signs Global Distribution Agreement with Children's Media Studio • AHRO • Aug 15, 2024 8:45 AM
POET Technologies Reports Second Quarter 2024 Financial Results • POET • Aug 15, 2024 8:04 AM